Excess risk of subsequent infection in hospitalized children from a community cohort study in Cambodia and Madagascar.

Children care pathway cohort diarrhoea global health hospital infection low- and middle-income countries lower-respiratory infection post-hospital syndrome sepsis

Journal

International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871

Informations de publication

Date de publication:
13 10 2022
Historique:
received: 28 06 2021
accepted: 09 03 2022
pubmed: 26 3 2022
medline: 15 10 2022
entrez: 25 3 2022
Statut: ppublish

Résumé

Children in low- and middle-income countries are particularly vulnerable in the months following an initial health event (IHE), with increased risk of mortality caused mostly by infectious diseases. Due to exposure to a wide range of environmental stressors, hospitalization in itself might increase child vulnerability at discharge. The goal of this study was to disentangle the role of hospitalization on the risk of subsequent infection. Data from a prospective, longitudinal, international, multicenter mother-and-child cohort were analysed. The main outcome assessed was the risk of subsequent infection within 3 months of initial care at hospital or primary healthcare facilities. First, risk factors for being hospitalized for the IHE (Step 1) and for having a subsequent infection (Step 2) were identified. Then, inpatients were matched with outpatients using propensity scores, considering the risk factors identified in Step 1. Finally, adjusted on the risk factors identified in Step 2, Cox regression models were performed on the matched data set to estimate the effect of hospitalization at the IHE on the risk of subsequent infection. Among the 1312 children presenting an IHE, 210 (16%) had a subsequent infection, mainly lower-respiratory infections. Although hospitalization did not increase the risk of subsequent diarrhoea or unspecified sepsis, inpatients were 1.7 (95% Confidence Intervals [1.0-2.8]) times more likely to develop a subsequent lower-respiratory infection than comparable outpatients. For the first time, our findings suggest that hospitalization might increase the risk of subsequent lower-respiratory infection adjusted on severity and symptoms at IHE. This highlights the need for robust longitudinal follow-up of at-risk children and the importance of investigating underlying mechanisms driving vulnerability to infection.

Sections du résumé

BACKGROUND
Children in low- and middle-income countries are particularly vulnerable in the months following an initial health event (IHE), with increased risk of mortality caused mostly by infectious diseases. Due to exposure to a wide range of environmental stressors, hospitalization in itself might increase child vulnerability at discharge. The goal of this study was to disentangle the role of hospitalization on the risk of subsequent infection.
METHODS
Data from a prospective, longitudinal, international, multicenter mother-and-child cohort were analysed. The main outcome assessed was the risk of subsequent infection within 3 months of initial care at hospital or primary healthcare facilities. First, risk factors for being hospitalized for the IHE (Step 1) and for having a subsequent infection (Step 2) were identified. Then, inpatients were matched with outpatients using propensity scores, considering the risk factors identified in Step 1. Finally, adjusted on the risk factors identified in Step 2, Cox regression models were performed on the matched data set to estimate the effect of hospitalization at the IHE on the risk of subsequent infection.
RESULTS
Among the 1312 children presenting an IHE, 210 (16%) had a subsequent infection, mainly lower-respiratory infections. Although hospitalization did not increase the risk of subsequent diarrhoea or unspecified sepsis, inpatients were 1.7 (95% Confidence Intervals [1.0-2.8]) times more likely to develop a subsequent lower-respiratory infection than comparable outpatients.
CONCLUSION
For the first time, our findings suggest that hospitalization might increase the risk of subsequent lower-respiratory infection adjusted on severity and symptoms at IHE. This highlights the need for robust longitudinal follow-up of at-risk children and the importance of investigating underlying mechanisms driving vulnerability to infection.

Identifiants

pubmed: 35333344
pii: 6554034
doi: 10.1093/ije/dyac048
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1421-1431

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.

Auteurs

Lison Rambliere (L)

Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.

Elsa Kermorvant-Duchemin (E)

Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, Department of Neonatology and Université de Paris, Paris, France.

Agathe de Lauzanne (A)

Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, 12201 Phnom Penh, Cambodia.

Jean-Marc Collard (JM)

Institut Pasteur de Madagascar, Unité de bactériologie expérimentale, Antananarivo, Madagascar.

Perlinot Herindrainy (P)

Institut Pasteur de Madagascar, Unité d'épidémiologie et de Recherche Clinique, Antananarivo 101, Madagascar.

Muriel Vray (M)

Institut Pasteur de Dakar, Unité d'épidémiologie des Maladies Infectieuses, Dakar, Senegal.

Benoit Garin (B)

Laboratoire Hématologie-Immunologie/Secteur HLA, CHU Pointe-à-Pitre/ Abymes, Pointe-à-Pitre, Guadeloupe.

Andrianirina Zafitsara Zo (AZ)

Peadiatric Ward, Centre Hospitalier de Soavinandriana, Antananarivo, Madagascar.

Fanjalalaina Rasoanaivo (F)

Institut Pasteur de Madagascar, Unité d'épidémiologie et de Recherche Clinique, Antananarivo 101, Madagascar.

Jacob Rakotoarimanana Feno Manitra (J)

Institut Pasteur de Madagascar, Unité d'épidémiologie et de Recherche Clinique, Antananarivo 101, Madagascar.

Tanjona Bodonirina Raheliarivao (TB)

Institut Pasteur de Madagascar, Unité d'épidémiologie et de Recherche Clinique, Antananarivo 101, Madagascar.

Jean-Baptiste Niokhhor Diouf (JN)

Centre Hospitalier Roi Baudouin Guédiawaye, Dakar Senegal.

Véronique Ngo (V)

Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, 12201 Phnom Penh, Cambodia.

Siyin Lach (S)

Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, 12201 Phnom Penh, Cambodia.

Pring Long (P)

Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, 12201 Phnom Penh, Cambodia.

Laurence Borand (L)

Institut Pasteur du Cambodge, Epidemiology & Public Health Unit, Phnom Penh, 12201 Phnom Penh, Cambodia.

Touch Sok (T)

Ministry of Health, Phnom Penh, Cambodia.

Armiya Youssouf Abdou (AY)

Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.

Michael Padget (M)

Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.

Yoann Madec (Y)

Institut Pasteur, Epidemiology of Emerging Disease, Paris, France.

Didier Guillemot (D)

Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.
AP-HP. Paris Saclay, Public Health, Medical Information, Clinical Research, Le Kremlin-Bicêtre, France.

Elisabeth Delarocque-Astagneau (E)

Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.
AP-HP. Paris Saclay, Public Health, Medical Information, Clinical Research, Le Kremlin-Bicêtre, France.

Bich-Tram Huynh (BT)

Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.
Université Paris-Saclay, UVSQ, Inserm, CESP, Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-le-Bretonneux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH